Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493487 | 0.84 | ALDH1A1 (0.79) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL1493435 | 0.84 | ALDH1A1 (0.79) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL6279510 | 0.83 | KMT2A (0.73) | POLBKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL859415 | 0.82 | ALDH1A1 (0.74) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL1610031 | 0.81 | POLB (1.00) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL1493362 | 0.81 | MAPK1 (0.78) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL7992707 | 0.80 | POLB (0.97) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL6273823 | 0.79 | KMT2A (1.00) | POLBKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1493401 | 0.79 | ALDH1A1 (0.64) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL23009199 | 0.78 | ALDH1A1 (0.63) | KMT2AMEN1MAPK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | POLB 4782/4885KMT2A 1510/4885MEN1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.